ADVFN US – Market Content Editor
-

Salarius shares jump after rebranding announcement to Decoy Therapeutics
Shares of Salarius Pharmaceuticals Inc (NASDAQ:SLRX) climbed 11.7% in premarket trading on Wednesday after the company said it will rebrand as Decoy Therapeutics Inc. and begin trading under the new ticker symbol “DCOY” from January 8, 2026. The Cambridge, Massachusetts–based group said the name change underscores a strategic pivot toward the development of peptide-conjugate therapeutics,…
-

Cardio Diagnostics shares jump after announcing first international expansion into India
Shares of Cardio Diagnostics Holdings Inc (NASDAQ:CDIO) climbed about 9.3% in premarket trading on Wednesday after the company unveiled plans to expand into India, marking its first move beyond the U.S. market. The AI-enabled cardiovascular diagnostics specialist said it has entered into a strategic partnership to introduce its PrecisionCHD blood test in India. The collaboration…
-

HUTCHMED shares edge higher after Phase III success for sovleplenib in wAIHA
Shares of HUTCHMED (NASDAQ:HCM) rose around 1.9% in premarket trading on Wednesday after the company reported positive Phase III results for sovleplenib in patients with warm antibody autoimmune hemolytic anemia (wAIHA). The company said its pivotal ESLIM-02 study met the primary endpoint, with sovleplenib — a next-generation spleen tyrosine kinase (SYK) inhibitor — delivering a…
-

Kamada shares climb after upbeat 2026 outlook points to double-digit growth
Shares of Kamada Ltd. (NASDAQ:KMDA) rose about 8% after the biopharmaceutical group released its financial guidance for 2026, forecasting another year of strong double-digit growth in both revenue and earnings. The Israel-based specialist in plasma-derived therapies said it expects 2026 revenue to reach between $200 million and $205 million, alongside adjusted EBITDA of $50 million…
-

Aspire Biopharma shares surge after FDA talks support heart attack drug pathway
Shares of Aspire Biopharma Holdings Inc (NASDAQ:ASBP) jumped more than 60% in premarket trading on Wednesday after the company said a pre-IND meeting with the Food and Drug Administration had produced positive feedback for its emergency heart attack treatment. Aspire said the FDA endorsed its proposed regulatory approach for OTASA, a sublingual aspirin powder intended…
-

UniFirst shares drop after Q1 earnings fall short despite revenue beat
Shares of UniFirst Corporation (NYSE:UNF) slid about 5% in premarket trading on Wednesday after the company posted first-quarter results that missed profit expectations, even as revenue edged past forecasts. For its fiscal first quarter ended November 29, 2025, the uniform and facility services provider reported adjusted earnings per share of $1.89, below the $2.10 analysts…
-

AST SpaceMobile shares slide after Scotiabank cuts rating to Underperform
Shares of AST SpaceMobile (NASDAQ:ASTS) dropped 6.8% in premarket trading on Wednesday after Scotiabank downgraded the satellite communications firm from Sector Perform to Sector Underperform. The downgrade came from analyst Andres Coello, who also set a new price target of $45.60, pointing to valuation concerns and ongoing operational hurdles. At Tuesday’s closing price of $97.60,…
-

Munters shares slide as NVIDIA’s Rubin chip signals shift in data center cooling standards
Shares in Munters (USOTC:MMNNF) fell by more than 5% on Wednesday after NVIDIA unveiled details of its new Rubin chip, which is designed to operate at substantially higher temperatures than conventional data center processors. NVIDIA (NASDAQ:NVDA) said the Rubin chip can run efficiently at temperatures of around 42–45°C (108–113°F), a sharp contrast to traditional chilled-water…
-

Compass Pathways gains after FDA clears IND for PTSD trial of COMP360
Shares of Compass Pathways Plc (NASDAQ:CMPS) rose about 3% in premarket trading on Wednesday after the company said the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for COMP360, paving the way for a late-stage study in patients with post-traumatic stress disorder. With the IND now in place, Compass will…
-

Netflix reiterates support for $82.7bn Warner Bros. Discovery merger after rival bid rejected
Netflix (NASDAQ:NFLX) said it remains fully committed to its $82.7 billion merger agreement with Warner Bros. Discovery (NASDAQ:WBD), after Warner Bros. Discovery’s board turned down a revised proposal from Paramount Skydance (NASDAQ:PARA). The Warner Bros. Discovery board concluded that the agreement with Netflix offers superior value for shareholders. Under the terms of the deal, Netflix…